Perioperative Complications and Long-Term Follow-Up of Liver Transplantation in Hemorrhagic Hereditary Telangiectasia: Report of Three Cases and Systematic Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 14

PMID 36233492

Authors

Antoni Riera-Mestre

Pau Cerda

Yoelimar Carolina Guzman

Adriana Iriarte

Alba Torroella

Jose Maria Mora-Lujan

Jose Castellote

Amelia Hessheimer

Constantino Fondevila

Laura Llado

Affiliations

Soon will be listed here.

Abstract

The aim was to describe three patients with hemorrhagic hereditary telangiectasia (HHT) requiring liver transplantation (LT) and to perform a systematic review focusing on surgical complications and long-term follow-up. Unrestricted searches of the Medline and Embase databases were performed through February 2022. Forty-five studies were selected including 80 patients plus the three new reported patients, 68 (81.9%) were female and mean age was 50 (27-72) years. Main indications for LT were high-output cardiac failure ( = 40; 48.2%), ischemic cholangitis ( = 19; 22.9%), and a combination of both conditions ( = 13;15.6%). Mean cold ischemic time and red blood cell units transfused during LT were 554 (300-941) minutes and 11.4 (0-88) units, respectively. Complications within 30 days were described in 28 (33.7%) patients, mainly bleeding complications in 13 patients, hepatic artery (HA) thrombosis in four and hepatic vein thrombosis in one. Mean follow-up was 76.4 (1-288) months, and during it, four new patients developed thrombotic complications in HA, HA aneurysm, celiac artery, and the portal-splenic-mesenteric vein. HHT relapse in the transplant allograft was detected in 13 (17.1%) patients after 1-19 years (including two fatal recurrences). Overall mortality was 12%. In conclusion, previous assessment of HA anatomy and hyperdynamic circulatory state could reduce LT complications. The risk of relapse in the hepatic graft supports a multidisciplinary follow-up for HHT patients with LT.

Citing Articles

Minimal encephalopathy in hereditary hemorrhagic telangiectasia patients with portosystemic vascular malformations.

Villanueva B, Canabate A, Torres-Iglesias R, Cerda P, Gamundi E, Ordi Q Orphanet J Rare Dis. 2024; 19(1):484.

PMID: 39709450 PMC: 11663308. DOI: 10.1186/s13023-024-03493-3.

Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia.

Ielasi L, Tonnini M, Piscaglia F, Serio I World J Hepatol. 2023; 15(5):675-687.

PMID: 37305373 PMC: 10251273. DOI: 10.4254/wjh.v15.i5.675.

References

Bauer T, Britton P, Lomas D, Wight D, Friend P, Alexander G . Liver transplantation for hepatic arteriovenous malformation in hereditary haemorrhagic telangiectasia. J Hepatol. 1995; 22(5):586-90. DOI: 10.1016/0168-8278(95)80455-2. View

Saxena R, Hytiroglou P, Atillasoy E, Cakaloglu Y, Emre S, Thung S . Coexistence of hereditary hemorrhagic telangiectasia and fibropolycystic liver disease. Am J Surg Pathol. 1998; 22(3):368-72. DOI: 10.1097/00000478-199803000-00013. View

Sabba C, Gallitelli M, Longo A, Cariati M, Angelelli G . Orthotopic liver transplantation and hereditary hemorrhagic telangiectasia: do hepatic vascular malformations relapse? A long term follow up study on two patients. J Hepatol. 2004; 41(4):687-9. DOI: 10.1016/j.jhep.2004.06.007. View

. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2015; 64(1):179-202. DOI: 10.1016/j.jhep.2015.07.040. View

Odorico J, Hakim M, Becker Y, van der Werf W, Musat A, Knechtle S . Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. Liver Transpl Surg. 1998; 4(6):483-90. DOI: 10.1002/lt.500040609. View

Mora-Lujan J, Iriarte A, Alba E, Sanchez-Corral M, Cerda P, Cruellas F . Gender differences in hereditary hemorrhagic telangiectasia severity. Orphanet J Rare Dis. 2020; 15(1):63. PMC: 7053104. DOI: 10.1186/s13023-020-1337-5. View

Hillert C, Broering D, Gundlach M, Knoefel W, Izbicki J, Rogiers X . Hepatic involvement in hereditary hemorrhagic telangiectasia: an unusual indication for liver transplantation. Liver Transpl. 2001; 7(3):266-8. DOI: 10.1053/jlts.2001.21313. View

Mitchell A, Adams L, MacQuillan G, Tibballs J, Vanden Driesen R, Delriviere L . Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 2008; 14(2):210-3. DOI: 10.1002/lt.21417. View

Brenard R, Chapaux X, Deltenre P, Henrion J, De Maeght S, Horsmans Y . Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. Eur J Gastroenterol Hepatol. 2010; 22(10):1253-9. DOI: 10.1097/MEG.0b013e32833ac4a1. View

10.

Vazquez C, Gonzalez M, Ferraris A, Bandi J, Serra M . Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS One. 2020; 15(2):e0228486. PMC: 7006931. DOI: 10.1371/journal.pone.0228486. View

11.

Ionescu M, Edwin I, Wilson C, Saikia S, Talbot D . Orthotopic Liver Transplantation for Hereditary Hemorrhagic Telangiectasia and MEN Type I Syndrome - Case Report and Review of Literature. Chirurgia (Bucur). 2019; 113(6):837-848. DOI: 10.21614/chirurgia.113.6.837. View

12.

Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G . Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci. 2011; 56(7):2166-78. PMC: 3112486. DOI: 10.1007/s10620-011-1585-2. View

13.

Perrodin S, Vogt A, Berzigotti A, Kim-Fuchs C, Luedi M, Candinas D . Resolution of Precapillary Pulmonary Hypertension After Liver Transplantation for Hereditary Hemorrhagic Telangiectasia: Systematic Review and Case Report. Transplant Proc. 2022; 54(1):135-143. DOI: 10.1016/j.transproceed.2021.11.010. View

14.

Ejiri K, Akagi S, Nakamura K, Amioka N, Ichikawa K, Yagi T . Liver transplantation in a patient with hereditary haemorrhagic telangiectasia and pulmonary hypertension. Pulm Circ. 2020; 9(4):2045894019896677. PMC: 6923528. DOI: 10.1177/2045894019896677. View

15.

Chavan A, Luthe L, Gebel M, Barg-Hock H, Seifert H, Raab R . Complications and clinical outcome of hepatic artery embolisation in patients with hereditary haemorrhagic telangiectasia. Eur Radiol. 2012; 23(4):951-7. PMC: 3599206. DOI: 10.1007/s00330-012-2694-9. View

16.

Ulus S, Arslan A, Karaarslan E, Cakaloglu Y . De Novo Vascular Lesions After Liver Transplant in a Case With Hereditary Hemorrhagic Telangiectasia and Fibropolycystic Liver Disease: Long-Term Follow-Up With Magnetic Resonance Imaging and Magnetic Resonance Angiography. Exp Clin Transplant. 2016; 17(1):115-118. DOI: 10.6002/ect.2016.0024. View

17.

Aseni P, Vertemati M, Minola E, Bonacina E . Massive haemoptysis after living donor liver transplantation. J Clin Pathol. 2003; 56(11):876-8. PMC: 1770121. DOI: 10.1136/jcp.56.11.876. View

18.

Geisthoff U, Nguyen H, Hess D . Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann Hematol. 2013; 93(4):703-4. DOI: 10.1007/s00277-013-1845-7. View

19.

Ahumada V, Tejos R, Moraga F, Achurra P, Godoy I, Loyola S . [Liver transplant as treatment for cardiac failure secondary to hereditary hemorrhagic telangiectasia. Report of one case]. Rev Med Chil. 2017; 145(6):799-803. DOI: 10.4067/s0034-98872017000600799. View

20.

Lerut J, Orlando G, Adam R, Sabba C, Pfitzmann R, Klempnauer J . Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. Ann Surg. 2006; 244(6):854-62. PMC: 1856634. DOI: 10.1097/01.sla.0000247258.35406.a4. View